drugset / Trial / NCT02121288

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

NCT02121288 ↗

Phase 4 Withdrawn AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the effect of blood flow to the heart when subjects are treated with ticagrelor (Brilinta) or clopidogrel (antiplatelet drugs that stop the blood from clumping together) in patients with Peripheral Artery Disease (PAD).

Timeline

Start
2014-12
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg Oral
Subject Ticagrelor Small molecule 90 mg Oral